Inhibition of NF-κB–Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma

Abstract excerpt

Abstract Bromodomain and extraterminal protein inhibitors (BETi) are epigenetic therapies aimed to target dysregulated gene expression in cancer cells. Despite early successes of BETi in a range of malignancies, the development of drug resistance may limit their clinical application. Here, we evaluated the mechanisms of BETi resistance in uveal melanoma, a disease with little treatment options, using two...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Multiple Myeloma Research and Treatments
• Share to Ocular Oncology and Treatments
• Share to Protein Degradation and Inhibitors